Arrowstreet Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Arrowstreet Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-48,453	Closed	-$612K	–	2633
2020 Q4	$612K	Sell	48,453 -14,400	-23%	-$164K	﹤0.01%	1964
2020 Q3	$617K	Buy	62,853 +34,003	+118%	+$335K	﹤0.01%	1961
2020 Q2	$287K	Buy	28,850 +6,724	+30%	+$64.5K	﹤0.01%	2116
2020 Q1	$196K	Buy	22,126 +8,226	+59%	+$81.1K	﹤0.01%	1735
2019 Q4	$128K	Buy	+13,900	New	+$98.5K	﹤0.01%	1654
2018 Q4	–	Sell	-297,864	Closed	-$4.42M	–	1550
2018 Q3	$4.42M	Sell	297,864 -3,786	-1%	-$59.6K	0.01%	531
2018 Q2	$5.08M	Buy	301,650 +9,700	+3%	+$188K	0.01%	543
2018 Q1	$6.69M	Buy	291,950 +183,250	+169%	+$4.08M	0.02%	520
2017 Q4	$2.81M	Buy	+108,700	New	+$2.19M	0.01%	731

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's CNCE Position: Q1 2021 in Review

Arrowstreet Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 48,453 shares — an estimated $612K sold.

Arrowstreet Capital first reported a position in CNCE in Q4 2017 and held it in 9 quarters. The position peaked at $6.69M in Q1 2018. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

Arrowstreet Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Arrowstreet Capital sold 48,453 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $612K.
Arrowstreet Capital first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 9 quarters.
Arrowstreet Capital's Concert Pharmaceuticals, Inc. position peaked at $6.69M in Q1 2018.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.